<DOC>
	<DOCNO>NCT02169453</DOCNO>
	<brief_summary>To investigate effect three single oral dos BIA 9-1067 ( 25 mg , 50 mg 100 mg ) levodopa pharmacokinetics administer combination single-dose controlled-release levodopa/carbidopa 100/25 mg ( Sinemet® CR 100/25 )</brief_summary>
	<brief_title>Pharmacokinetic-pharmacodynamic Interaction Between Each Three Different Single Doses BIA 9-1067 Single-dose Controlled-release 100/25 mg Levodopa/Carbidopa</brief_title>
	<detailed_description>Single centre , double-blind , randomize , placebo-controlled , crossover study four consecutive single-dose treatment period . The washout period dose least 14 day . On treatment period , completion pre-dose assessment , BIA 9-1067/Placebo administer concomitantly dose Sinemet® CR 100/25 ; post-dose assessment complete subject discharge 72 h post-dose . Subjects attend four treatment period receive different dose BIA 9-1067 ( 25 mg , 50 mg 100 mg ) placebo treatment period .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Opicapone</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Availability entire study period willingness adhere protocol requirement evidence informed consent form ( ICF ) duly read , sign date volunteer prior participation study . Male volunteer . Volunteers least 18 year age old 45 year . Volunteers body mass index ( BMI ) great equal 19 30 kg/m2 . Volunteers non exsmokers . An exsmoker define someone completely stop smoke least 12 month day 1 study . Volunteers healthy determine prestudy ( screen ) medical history , physical examination , vital sign , complete neurological examination 12lead ECG . Volunteers clinical laboratory test result judge clinically acceptable ( within laboratory 's state normal range ; within range , must without clinical significance ) screen admission first treatment period . Volunteers negative test hepatitis B surface antigen ( HBsAg ) , antihepatitis C antibody ( HCV Ab ) , Human immunodeficiency viruses 1 2 antibody ( HIV1 HIV2 Ab ) screening . Volunteers negative screen ethyl alcohol drug abuse screening . Due unknown risk potential harm unborn fetus , sexually active men must agree use medically acceptable form contraception throughout study . Volunteers conform inclusion criterion , case Volunteers clinically relevant surgical history . Volunteers clinically relevant family history . Volunteers history relevant atopy . Volunteers significant infection know inflammatory process screen first admission . Volunteers acute gastrointestinal symptom time screen first admission ( e.g. , nausea , vomit , diarrhoea , heartburn ) . Volunteers vegetarian , vegan medical dietary restriction . Volunteers could communicate reliably investigator . Volunteers unlikely cooperate requirement study . Significant history hypersensitivity BIA 91067 , tolcapone , entacapone , levodopa , carbidopa relate product ( include excipients formulation ) well severe hypersensitivity reaction ( like angioedema ) drug . Presence significant gastrointestinal , liver kidney disease , condition know interfere absorption , distribution , metabolism excretion drug know potentiate predispose undesired effect . History significant gastrointestinal , liver kidney disease may affect drug bioavailability . Presence history significant cardiovascular , pulmonary , hematologic , neurologic , psychiatric , lymphatic , musculoskeletal , genitourinary , endocrine , immunologic , dermatologic connective tissue disease . Suicidal tendency , history disposition seizure , state confusion , clinically relevant psychiatric disease . Presence significant heart disease disorder accord ECG . Presence suspicious undiagnosed skin lesion history melanoma . Previous history Neuroleptic Malignant Syndrome ( NMS ) and/or nontraumatic rhabdomyolysis . Presence history significant glaucoma . Used prescription medication include monoamine oxidase ( MAO ) inhibitor within 28 day day 1 study . Used overthecounter ( OTC ) product within 7 day day 1 study . Maintenance therapy drug , significant history drug dependency ( drug abuse ) alcohol abuse ( &gt; 3 unit alcohol per day , intake excessive alcohol , acute chronic ) . Any clinically significant illness previous 28 day day 1 study . Used enzymemodifying drug , include strong inhibitor cytochrome P450 ( CYP ) enzymes ( cimetidine , fluoxetine , quinidine , erythromycin , ciprofloxacin , fluconazole , ketoconazole , diltiazem HIV antiviral ) strong inducer CYP enzyme ( barbiturate , carbamazepine , glucocorticoid , phenytoin rifampicin ) , previous 28 day day 1 study . Volunteers take Investigational Product ( another clinical trial ) donate 50 mL blood previous 28 day day 1 study . Poor motivation , intellectual problem likely limit validity consent participate study limit ability comply protocol requirement inability cooperate adequately , inability understand observe instruction physician . Donation 500 mL blood ( Canadian Blood Services , HemaQuebec , clinical study , etc . ) previous 56 day day 1 study . Positive urine screen ethyl alcohol drug abuse admission treatment period . Any history tuberculosis and/or prophylaxis tuberculosis . Positive result HIV , HBsAg antiHCV test . Participation previous clinical study BIA 91067 within 84 day day 1 study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Parkinson 's disease ( PD )</keyword>
	<keyword>BIA 9-1067</keyword>
	<keyword>Opicapone</keyword>
</DOC>